Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | PEPD | P12955 | 2/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.48 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5499151 | 0.87 | FKBP1A (0.54) | POLBRAB9APEPDFKBP1AXPNPEP1 | |
| SCHEMBL3009794 | 0.87 | FKBP1A (0.54) | POLBRAB9APEPDFKBP1AXPNPEP1 | |
| SCHEMBL3009795 | 0.87 | FKBP1A (0.54) | POLBRAB9APEPDFKBP1AXPNPEP1 | |
| SCHEMBL1976765 | 0.84 | POLB (0.50) | POLBRAB9APEPDFKBP1AXPNPEP1 | |
| SCHEMBL3231642 | 0.84 | FKBP1A (0.51) | POLBRAB9APEPDFKBP1AXPNPEP1 | |
| SCHEMBL30599979 | 0.83 | POLB (0.58) | POLBRAB9APEPDFKBP1AXPNPEP1 | |
| SCHEMBL9546469 | 0.83 | POLB (0.58) | POLBRAB9APEPDFKBP1AXPNPEP1 | |
| SCHEMBL19334646 | 0.83 | FKBP1A (0.50) | POLBRAB9APEPDFKBP1AXPNPEP1 | |
| SCHEMBL15148125 | 0.82 | RAB9A (0.74) | POLBRAB9APEPDFKBP1AXPNPEP1 | |
| SCHEMBL13686730 | 0.82 | FKBP1A (0.52) | POLBRAB9APEPDFKBP1AXPNPEP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | SHIONOGI & CO., LTD. (JP) | 2021-06-22 | — | — | US | disclosed |
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | SHIONOGI & CO., LTD. (JP) | 2020-08-20 | — | — | US | disclosed |
| EP-2620436-B1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO (JP) | 2018-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | RNASEH1, RNASEL, RNPEP | POLB 107/4885RAB9A 2289/4885PEPD 368/4885 |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | RNASEH1, RNPEP, RNASEL | POLB 85/4885RAB9A 2120/4885PEPD 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.